T.TO 0.13ENB.TO 0.8BEP.UN.TO -1.15CP.TO 1.15VRT -19.67NVDA -7.33TSM -15.23JPM -6.1
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
HOLD

Pfizer Inc(PFE)

Oct 22, 2008
Losing Lipitor in a couple of years but thinks this is priced into the stock. They are doing cost cutting. Pipeline is a little weak. From a historic PE level and dividend it is a very attractive value. However, if the US is to regulate more and put price fixing on drugs, that would definitely be a negative.
Photo of David AbellaDavid Abella
Owned
Unlock Rating
$16.74

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 07, 2008
Interesting sock. Almost like a bond. Price assumes there will be no significant new drugs so revenue is based on existing drugs until they come off patent. No phase 2 drugs have hit over the last 2 years.
Photo of Charles BobrinskoyCharles BobrinskoyUnlock Rating
$17.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 16, 2008
Drugs are coming off patent and are they going to be able to replenish the pipeline? Does management have the ability to keep the cash flow chugging along? The market is telling you No. 7% yield but that there is very little else.
Photo of David DriscollDavid Driscoll
No
Unlock Rating
$17.81

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 11, 2008
Value manager’s dream but never has done anything. He has a model price of $30.26. 66% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$18.39

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 03, 2008
Trendline and 200-day moving average have been moving down. It has not made a base.
Photo of Ron MeiselsRon MeiselsUnlock Rating
$19.20

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 27, 2008
Owned it about a year ago with a theory that their drugs were worth what the stock price was going at hand you would make money on all the new drugs they developed. The problem is, they haven't developed any new drugs in almost 3 years. Would prefer Merck (MRK-N).
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$19.08

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2008
Worth considering at this price. Very cheap. Double-digit free cash flow yield and very attractive dividend yield. Lipitor will be coming off patent and pipeline of new drugs is relatively thin. Will be lucky to have 0% growth over the next 5 years but over the very long term they will get the pipeline filled.
Photo of Paul LarsonPaul Larson
Owned
Unlock Rating
$19.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 21, 2008
Pharmaceutical group is behaving better. This one is less attractive and is facing drugs coming off patent. Prefers others.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$19.37

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Aug 06, 2008
Earnings where fantastic. Yield of 6.6%.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$19.43

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Jul 16, 2008
At an interesting Buy point but not sure he would buy it currently. On his Watch list.
Photo of Peter BriegerPeter Brieger
No
Unlock Rating
$18.26

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Jul 11, 2008
(Market Call Minute.) Broken stock and he can't see what is going to turn it around.
Photo of David BurrowsDavid BurrowsUnlock Rating
$17.81

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 10, 2008
All of the big pharma have been very disappointing. Now yielding over 7% but doesn't think the dividend is in jeopardy as the cash flow is amazingly strong. Won't be a great investment for another year or so.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$18.03

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 04, 2008
Not cheap enough for him yet. He would have to go over the financial statements. There are a lot of companies in this area that may be of interest in the next few years.
Photo of Benj GallanderBenj Gallander
No
Unlock Rating
$17.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jun 11, 2008
Model price has been decreasing over the last 9 months, but not all that much. Thinks it will go down to $15.75 but he sees in setting up as a huge rally in healthcare related stocks in Q4 or Q1 of 09. Has an 86% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$17.55

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 10, 2008
Pharmaceutical industry in the US has been a disappointment for 2 or 3 years. There is concern about the new drug pipeline. Also a large number of blockbuster drugs are coming off patent for many companies. Also increased competition from generic companies. At 7.2%, the market is telling you it does not believe the dividend is safe.
Photo of David BaskinDavid BaskinUnlock Rating
$17.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 511 to 525 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TPZ.TO 0.13$12.73
KBL.TO 0.98$42.9
PPL.TO -0.14$66.12
AQN.TO 0.11$7.46
EMA.TO -0.02$68.17

Today's Top Picks

T.TO 0.13$12.73
ENB.TO 0.8$67.03
BEP.UN.T… -1.15$40.98
CP.TO 1.15$124.99
VRT -19.67$237.39

Popular Articles

Latest Sell Signals

CPX.TO 1.15$124.99
AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79

Most Recent Experts

Ryan Bushell

Ryan Bushell

Newhaven Asset Management

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like